Early effects of lipid lowering treatment in subjects with metabolic syndrome and acute coronary syndromes

International Journal of Atherosclerosis

Volumn 3, Issue 2, 2008, Pages 93-99

  Monteiro, Carlos M C ^a   Oliveira, Luciene ^a   Izar, Maria C O ^a   Santos, Andreza O ^a   Póvoa, Rui M S ^a   Fischer, Simone M ^a   Barros, Sahna W ^a   Carvalho, Antonio C C ^a   Fonseca, Francisco A H ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute coronary syndrome; C reactive protein; Hemostasis; Lipids; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; D DIMER; FENOFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NUTRITIONAL COUNSELING; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 67650289620     PISSN: 18092942     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4;288(21):2709-2716
2. McNeill AM, Rosamond WD, Girman CJ, Heiss G, Golden SH, Duncan BB, Ballantyne CM, Heiss G. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005 Feb;28(2):385-390
3. Feinberg MS, Schwartz R, Tanne D, Fisman EZ, Hod H, Zahger D, Schwammethal E. Eldar M, Behar S, Tenenbaum A. Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol. 2007Mar 1;99(5):667-672
4. Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Heman WH, Homan RR, Jones NP, Lachin JM, Viberti GC: ADOPT Study Group. Obesity is a major determinant of the associationof C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes. 2006 Aug;55(8):2357-2364 (Pubitemid 44743635)
5. Rector RS, Warner SO, Liu Y, Hinton PS, Sun GY, Cox RH, Stamp CS, Laughlin MH, Dellsperger KC, Thomas TRI. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Endocrinol Metab. 2007 Aug;293(6):E500-E506.
6. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, forder P, Pillai A, Davis T. Glacion P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnhom C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-1861
7. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol. 2007 Feb19;99(4A):27B-40B.
8. Turhan H, Yetkin E. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome? Int J Cardiol. 2006 Jun 16;110(2):276-277
9. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001 May16;285(19):2486-2497
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499-502.
11. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
12. Tenenbaum A, Fisman EZ. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both? Cardiovasc Diabetol. 2004 Dec 1;3:10.
13. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budai A, Pais P, Varigos J, Lishena L; INTERHEART Sutdy Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 sep 11-17;364(9438):937-952
14. Kim HK, Chang SA, Choi EK, Kim YJ, Kim HS, Sohn DW, Oh BH, Lee MM, Park YB, Choi YS. Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population. Int J Cardiol. 2005 Jun 8;101(3):435-440
15. Barter PJ, Rye K-A. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscl Thromb Vasc Biol. 2008 Jan;28(1):39-46.
16. Walldius G, Jungner I. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I-new risk factors and targets for therapy. Nutr Metab Cardiovasc Dis. 2007 Oct;17(8):565-571
17. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 Jul 13;110(2):227-239
18. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation. 1997 Dec 16;96(12):4204-4210
19. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999 Feb 23;99(7):855-860
20. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE-IT - TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. J Am Coll Cardiol. 2005 Oct 18;46(8):1405-1410 (Pubitemid 41446173)
21. Vergès B. Clinical interest of PPARs ligands. Diabetes Metab. 2004 Feb;30(1):7-12.
22. Arca M, Natoli S, Micheletta F, Riggi S, Di Angelantonio E, Montali A, antonini TM, Antnini R, Diszfalusy U, Juliano L. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. Free Radic Biol Med. 2007 Mar 1;42(5):698-705.
23. Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006 May;4(5):1029-1036
24. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med. 2000 Jul 18;133(2): 81-91.
25. Okopien B, Cwalina L, Lebek M, Kowalski J, Zielinski M, Wisniewska- Wanat M, Kalina Z, Herman ZS. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Int J Clin Pharmacol Ther. 2001 Dec;39(12):551-557 (Pubitemid 33130406)
26. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004 Sep 7;110(10):1245-1250
27. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D. Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert Ka, AHA/ACC; National Heart, Lund and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 May 16;113(19):2363-2372